Clinical trials / Bipolar disorder
Recruiting psychedelic and ketamine trials for bipolar disorder
6 trials registered on ClinicalTrials.gov were recruiting on 26 Oct 2026, 3 of them at sites in the United States (3 states). By substance: Ketamine / esketamine 4, Psilocybin 2.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Trials with US sites
ObservationalKetamine / esketamineNCT04480918
University of Iowa Interventional Psychiatry Service Patient Registry
- Conditions:
- Treatment Resistant Depression; Major Depressive Episode; Major Depression; Major Depressive Disorder; Bipolar Disorder; Bipolar Depression; Obsessive-Compulsive Disorder
- Sponsor:
- Mark Niciu
- Who:
- ages 18 Years to 99 Years, 1000 participants planned
- University of Iowa Health Care, Iowa City, Iowa
Phase 2Ketamine / esketamineNCT05786066
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- Conditions:
- Depressive Disorder; Major Depressive Disorder; Bipolar Disorder; Post Traumatic Stress Disorder; Suicidal Ideation
- Sponsor:
- Yale University
- Who:
- ages 21 Years to 65 Years, 30 participants planned
- VA Connecticut Healthcare System, West Haven, Connecticut
Phase 2PsilocybinNCT06706232
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
- Conditions:
- Bipolar II Disorder; Depression, Bipolar; Suicidality
- Sponsor:
- The University of Texas Health Science Center, Houston
- Who:
- ages 25 Years to 70 Years, 10 participants planned
- The University of Texas Health Science Center at Houston, Houston, Texas
Trials outside the United States
Phase 3Ketamine / esketamineNCT05603104
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (INTENSIFY)
- Conditions:
- Schizophrenia and Related Disorders; Major Depressive Disorder; Bipolar Depression
- Sponsor:
- Dr. Inge Winter
- Who:
- ages 18 Years to 70 Years, 1254 participants planned
- Where:
- Israel
Phase 2PsilocybinNCT06943573
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder (PAT-BD-01)
- Conditions:
- Bipolar II Depression
- Sponsor:
- Lakshmi N Yatham
- Who:
- ages 19 Years to 65 Years, 90 participants planned
- Where:
- Canada
Phase 2Ketamine / esketamineNCT07569198
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) (KET-DBT)
- Conditions:
- Borderline Personality Disorder (BPD); Treatment-Resistant Major Depressive Disorder; Treatment-resistant Bipolar Depression; Major Depressive Disorder (MDD); Bipolar Disorder (BD); Bipolar Disorder I or II; Suicidal Ideation
- Sponsor:
- Joshua Rosenblat
- Who:
- ages 18 Years to 70 Years, 120 participants planned
- Where:
- Canada